克服DCIS的过度治疗：来自PRECISION的教训。

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2025-01-13 DOI:10.1158/2159-8290.CD-24-1201

Proteeti Bhattacharjee, Esther H Lips, Elinor J Sawyer, E Shelley Hwang, Alastair M Thompson, Jelle Wesseling

{"title":"克服DCIS的过度治疗：来自PRECISION的教训。","authors":"Proteeti Bhattacharjee, Esther H Lips, Elinor J Sawyer, E Shelley Hwang, Alastair M Thompson, Jelle Wesseling","doi":"10.1158/2159-8290.CD-24-1201","DOIUrl":null,"url":null,"abstract":"As we cannot reliably distinguish indolent, low-risk ductal carcinoma in situ (DCIS) from potentially progressive, high-risk DCIS, all women with DCIS diagnosis undergo intensive treatment without any benefit. The PREvent ductal Carcinoma In Situ Invasive Overtreatment Now team was established to unravel DCIS biology and develop new multidisciplinary approaches for accurate risk stratification to tackle the global problem of DCIS overdiagnosis and overtreatment. See related article by Bressan et al., p. 16 See related article by Stratton et al., p. 22 See related article by Goodwin et al., p. 34.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"15 1","pages":"28-33"},"PeriodicalIF":29.7000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Conquering Overtreatment of DCIS: Lessons from PRECISION.\",\"authors\":\"Proteeti Bhattacharjee, Esther H Lips, Elinor J Sawyer, E Shelley Hwang, Alastair M Thompson, Jelle Wesseling\",\"doi\":\"10.1158/2159-8290.CD-24-1201\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"As we cannot reliably distinguish indolent, low-risk ductal carcinoma in situ (DCIS) from potentially progressive, high-risk DCIS, all women with DCIS diagnosis undergo intensive treatment without any benefit. The PREvent ductal Carcinoma In Situ Invasive Overtreatment Now team was established to unravel DCIS biology and develop new multidisciplinary approaches for accurate risk stratification to tackle the global problem of DCIS overdiagnosis and overtreatment. See related article by Bressan et al., p. 16 See related article by Stratton et al., p. 22 See related article by Goodwin et al., p. 34.\",\"PeriodicalId\":9430,\"journal\":{\"name\":\"Cancer discovery\",\"volume\":\"15 1\",\"pages\":\"28-33\"},\"PeriodicalIF\":29.7000,\"publicationDate\":\"2025-01-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/2159-8290.CD-24-1201\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2159-8290.CD-24-1201","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

由于我们不能可靠地区分惰性、低风险的导管原位癌（DCIS）和潜在进展性、高风险的DCIS，所有确诊为DCIS的女性都接受了强化治疗，但没有任何益处。预防导管癌原位浸润性过度治疗小组的成立是为了揭示DCIS生物学，并开发新的多学科方法来准确地进行风险分层，以解决DCIS过度诊断和过度治疗的全球性问题。参见布雷桑等人的相关文章，第16页。参见斯特拉顿等人的相关文章，第22页。参见古德温等人的相关文章，第34页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Conquering Overtreatment of DCIS: Lessons from PRECISION.

As we cannot reliably distinguish indolent, low-risk ductal carcinoma in situ (DCIS) from potentially progressive, high-risk DCIS, all women with DCIS diagnosis undergo intensive treatment without any benefit. The PREvent ductal Carcinoma In Situ Invasive Overtreatment Now team was established to unravel DCIS biology and develop new multidisciplinary approaches for accurate risk stratification to tackle the global problem of DCIS overdiagnosis and overtreatment. See related article by Bressan et al., p. 16 See related article by Stratton et al., p. 22 See related article by Goodwin et al., p. 34.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.